AEterna Zentaris Inc. (NASDAQ: AEZS) is climbing in the market this morning, but there has been no press releases or SEC filings released. So, what’s the deal?
The CHMP for the EMA released highlights from its recent meeting. The meeting took place from November 12 through November 15.
During the meeting, the CHMP discussed the potential approval of various treatments, one of which is the flagship treatment at AEZS. This treatment is known as Macimorelin.
In the meeting highlights, the CHMP announced that they recommended the treatment for marketing authorization approval in the EU.
The CHMP does not make final decisions with regard to marketing authorization approval. However, the committee is an imporatnt advisor to the EMA. In most cases, when the CHMP recommends approval, that’s exactly what the EMA does.
With that considered, chances are that AEZS will enjoy EMA approval. This means that Macimorelin will likely soon be able to be marketed to the various EU member nations.
As a result of the news, AEterna Zentaris is flying in the market today. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:29), AEZS is trading at $2.66 per share after a gain of $0.12 per share or 4.72% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Read our full report on this AEZS story here!